Novo Nordisk’s Brazilian Generic Setback Adds Urgency to ADA Pipeline Showcase
Published on 05/28/2026 at 04:01 | Redaktion boerse-global.de
Novo Nordisk is entering a decisive stretch. The Danish drugmaker just lost the first chunk of its Ozempic monopoly in an emerging market — Brazil approved a generic copy that will undercut the original by 30% — while simultaneously preparing to unveil late-stage data on its most important pipeline candidate at a major diabetes conference. The juxtaposition underscores how the company must now defend its franchise even as it tries to prove it can evolve beyond it.
Brazil’s health regulator ANVISA gave the green light on 26 May 2026 to “Ozivy”, a synthetic semaglutide produced by local pharma EMS. It is the first approved generic of Novo Nordisk’s blockbuster Ozempic in the country, made possible by the expiration of patent protection in March. EMS intends to price Ozivy roughly 30% below the original and is producing it at its São Paulo plant, which has the capacity to churn out up to 40 million injection pens a year. Analysts estimate the Brazilian GLP?1 market will reach 17 billion Brazilian reais in 2026; EMS itself expects first?year sales of Ozivy to exceed 500 million reais. At least 17 other companies have filed for regulatory approval of their own semaglutide versions in Brazil.
On the same day, Novo Nordisk announced price cuts for Ozempic in Canada, rolling out a discount programme with pharmacy cards for patients lacking public or private insurance. The measure applies across all Canadian provinces except Quebec. The move is a direct response to the arrival of cheaper alternatives in that market, mirroring the pressure now building in Latin America.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Against this backdrop, all eyes are turning to New Orleans. From 5 to 8 June, the American Diabetes Association (ADA) will host its 86th annual meeting, and Novo Nordisk is scheduled to present 40 abstracts. The centrepiece is the Phase?3 data from the REIMAGINE?1–3 studies of CagriSema, the combination therapy targeting blood?glucose control and weight reduction in type?2 diabetes. The data will be unveiled in a symposium on Sunday, 7 June, at 22:30 Central European Summer Time. Also on the docket are Phase?2 results for the once?weekly candidate Zenagamtid and updated findings on established GLP?1 therapies. For investors, the session is a litmus test for whether CagriSema can credibly position itself as the next growth engine.
The pipeline focus comes at a time when Novo Nordisk’s financials are sending mixed signals. First?quarter reported sales rose 24% to 96.8 billion Danish kroner and operating profit jumped 54%, but those figures were flattered by a one?off effect in the US business. On an adjusted basis, net revenue fell 10% to 70.1 billion kroner and adjusted operating income dropped 15%. The company nonetheless raised its full?year guidance, albeit while still forecasting a decline of 4% to 12% in both top? and bottom?line adjusted numbers.
The stock reflects the uncertainty. It traded around €38.40?38.58 on Wednesday, nearly 10% above its 50?day moving average but more than 38% below last year’s high of €70.13. The relative strength index sits at 53, indicating neutral momentum. Novo Nordisk continues to buy back its own shares: the 15?billion?kroner programme launched in February has so far repurchased roughly 17 million B?shares for a total of 4.47 billion kroner. The company now holds about 34.2 million treasury B?shares, equivalent to 0.8% of total capital.
The real test, however, will come on 7 June, when the fresh efficacy and safety data from the CagriSema trials will either shore up confidence in the pipeline or raise further questions. Novo Nordisk will also host a dedicated R&D investor event that day and report half?year numbers on 5 August. For now, the ADA conference gives the market its best look yet at whether the company can reduce its dependence on semaglutide — just as the first generic copies of that very drug start to hit pharmacy shelves.
Ad
Novo Nordisk Stock: New Analysis - 28 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
